GlassScriptPhysician profile
Alisha Rose Welsh
NPI 1184398810
$2,406.38
in general payments reported to CMS, 2019-2025
33 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.68 · 2023: $416 · 2024: $684 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $490.28 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Vanda Pharmaceuticals INC. | $193.56 | 2024-2025 | Fanapt |
| Glaxosmithkline, LLC. | $159.43 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $149.79 | 2023-2025 | |
| Novo Nordisk INC | $143.22 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $131.62 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $102.53 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.71 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $92.24 | 2024-2025 | Jardiance, Zepbound, Emgality |
| Antares Pharma, INC. | $89.21 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $81.56 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Alkermes, INC. | $76.94 | 2023-2024 | Vivitrol, Vivitrol |
| Amgen INC. | $61.73 | 2024-2025 | Otezla, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $40.68 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $39.71 | 2025 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $39.21 | 2023 | |
| Pfizer INC. | $38.56 | 2025 | |
| Alexion Pharmaceuticals, INC. | $38.16 | 2023-2024 | Strensiq |
| Qol Medical, LLC | $37.94 | 2023-2025 | Sucraid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.29 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.70 | 2023-2024 | Ofev, Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $27.01 | 2023 | Ajovy |
| Boston Scientific Corporation | $25.22 | 2025 | Wavewriter Alpha Prime 16 |
| Ani Pharmaceuticals, INC. | $25.00 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.55 | 2024 | Rexulti |
| Biogen, INC. | $20.30 | 2024 | Spinraza |
| Dexcom, INC. | $20.06 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.12 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $17.70 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $17.40 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $16.69 | 2023 | |
| Astellas Pharma US INC | $14.07 | 2025 | Veozah |
| Tolmar, INC. | $13.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.